Posted by Michael Wonder on 25 Jul 2023
Health Canada approves AbbVie's Rinvoq (upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis
25 July 2023 - Approval is based on results from three Phase 3 studies: two for induction and one for maintenance.
AbbVie today announced that Health Canada has approved Rinvoq (upadacitinib, 45 mg [induction dose] and 15 mg and 30 mg [maintenance dose]), an oral, once daily selective and reversible JAK inhibitor, for the treatment of adults with moderately to severely active ulcerative colitis who have demonstrated prior treatment failure, i.e., an inadequate response to, loss of response to, or intolerance to at least one of conventional, and/or biologic therapy.
